Member Info for stu485

MrI,

You posed a good question and instead of others attempting to answer, they deflect from the question with personal abuse.It demonstrates the only answer to your question leads to a narrative they’d rather avoid.

The answer to your question is very simple;

-Risk of dilution in further funding .

-Risk of HCarT failing through testing.

Strange how dhub & Ping are not buying more given they feel it’s such an opportunity right now !

DYOR

AIMO

Yes Saint, that’s true.

I note you or indeed any other, avoids answering the very valid question Jim posed!?

Anyway, TW’s back so someone thinks it’s time for a push.

I believe JFH will be proven correct but sure TW and others will give it their best.

DYOR

AIMO

Mr I,

I don’t think they had any choice but to leave .

Maybe the FCA’s Pandora’s box JFH opened, backfired!!!??

AIMO

Read it and digest.

There’s nothing more to know !

Seawolf,

Provided Prevail are contracted for the Ph1 works to the value of their investment, i suspect they would not care one way or the other.

The warranties involved with their investment will ensure that happens.

I wouldn’t worry to much though on the, going private risk as Dingo’s going to reassure all with a post he claims is the company assurance they will not go down that route.

Dingo !?

AIMO

Actually i’d agree with Haywain’s thoughts on first patient likely outcome and so Ph1 patient trial, IF and when it happens, is not my main concern.

The interim period and funding is!

The large short position opened is not mine and like others, i have no idea when news will drop on just how and when the funding issue will be addressed.

Mr I, please give it a rest with the stale Mcap argument.

JFH over did it too and look what position he’s now in !?

AIMO

DYOR

Ps I’ll not be replying .

Haywain,

Thank you for the response.

It appears fair and unbiased , although with a positive slant as you openly admit.

More of the same might benefit this board.

AIMO

DYOR

Haywain, your recent posts regarding Ph1- first patient are all efficacy related.

We all know Ph1 is predominantly a safety study, so why no mention of safety stats?

In your defence and on a very quick look, I can’t see any asking for your scientific and unbiased opinion on safety, so let me please.

Could you please advise the typical CRS incident rate with Car T treatments ?

Also, in the unfortunate event of a severe CRS incident in Patient 1, do you believe the trial would continue?

Thanks in advance.

AIMO

DYOR

HT,

Yes that’s one possible explanation, there are others!!

AIMO

Ps Shicky’s still waiting.

Haywire,

I’m happy you reminded me.

Yes , at present my prediction on the FDA’s concerns( not mine !) on the issue raised, has not resulted in any significant impact to those therapies and as such, presently my opinion has proven incorrect.

Always happy to stand corrected .

How is it , ahead of time your repeated posting of maybe 3 patients being dosed , ( very specific) and now the company confirming the same are so precise?

Congratulations on being spot on !!

AIMO

HT,

I’ve previously answered you !… No.

I think Dhub mentioned he was . Maybe he can help you with whatever related question you have.

Probably you could give Shicky some more details with respect to his/her question as a knowledgeable LTH.

AIMO

Shicky,

Check out C4X and their recent RNS’s should you want to learn more on the de-listing and private company theme.

I’m not suggesting Hemo’ will , although many here intimating within recent posts, the possibility and logic to do so.

Maybe ask one of those posters for more details.

AIMO

😳

HT,

No.

What some are also finding amazing/concerning, is your knowledge of my specific location earlier this year that had not been divulged by me.

AIMO

Chaps,

Unlike others here, I’m very happy to answer your question.

My opinion on the timing of the previous placing was based on two aspects;

One, company announcements & two , the so called LTH’s (a specific group) postings and predictions on this board.

That same specific group are now making noises ( at least three recent and separate posts) of the possibility of de-listing and the company going private!

It’s interesting others have now recognized the MO of said same group.

Any other questions?

AIMO

HK,

It seems your not prepared to answer the question on this LSE board, as is your prerogative.

Maybe you’ll answer the question should others ask within a more formal arena.

AIMO

HK,

How about we concentrate on the real world and you answer the question previously posed , which I’m VERY confident it’s not just me who’d like to hear the answer.

AIMO

HK,

Why did you specifically mention a company who recently de-listed , when it had no relevance to the point you were communicating within your earlier post ?

Some may have perceived as a threat of such action , particularly if you were to believe JHFH’s conviction of who you really are !

Hopefully he’s wrong.

AIMO

HK,

Yeah, let’s stop the speculation !

We should all just wait to find out how the company is going to raise/secure the significant funds it says it needs.

( Company RNS ,…fact).

As a person keen on quoting stats, maybe you could work out for all to consider;

-of the previous funding rounds what percentage were none diluting to the relevant holders at raise.

I suspect a stat your not so keen to share !

AIMO

Simon Z,

Maybe new socks this time 😉